OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma

Nature

Volumn 467, Issue 7311, 2010, Pages 86-90

  Medina, Pedro P ^a   Nolde, Mona ^a,b   Slack, Frank J ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; DOXYCYCLINE; MICRORNA; MICRORNA 21; ONCOMIR; ONCOPROTEIN; TET PROTEIN; UNCLASSIFIED DRUG; MIRN21 MICRORNA, MOUSE;

APOPTOSIS; CANCER; CARCINOGEN; CYTOGENETICS; EXPERIMENTAL STUDY; GENE EXPRESSION; GENETIC DIFFERENTIATION; METABOLISM; MITOCHONDRIAL DNA; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRE B CELL LYMPHOMA; PRE B LYMPHOCYTE; PRIORITY JOURNAL; TUMOR CLASSIFICATION; TUMOR REGRESSION; ANIMAL; C57BL MOUSE; GENETICS; METABOLISM; TRANSGENIC MOUSE;

ANIMALS; LYMPHOMA, B-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; PRECURSOR CELLS, B-LYMPHOID;

MUS;

EID: 77956339881     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature09284     Document Type: Article

References (29)

1. Medina, P. P. & Slack, F. J. microRNAs and cancer: An overview. Cell Cycle 7, 2485-2492 (2008).
2. Esquela-Kerscher, A. & Slack, F. J. Oncomirs\microRNAs with a role in cancer. Nature Rev. Cancer 6, 259-269 (2006).
3. Sharma, S. V. & Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007).
4. Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077-3080 (2008).
5. Costinean, S. et al. Ship and C/ebp-b are targeted by miR-155 in B cells of Em-miR-155 transgenic mice. Blood 117, 1374-1382 (2009).
6. Si, M. L. et al. miR-21-mediated tumor growth. Oncogene 26, 2799-2803 (2007).
7. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-7070 (2005).
8. Chan, J. A., Krichevsky, A. M. & Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65, 6029-6033 (2005).
9. Schetter, A. J. et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. J. Am. Med. Assoc. 299, 425-436 (2008).
10. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261 (2006).
11. Fulci, V. et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109, 4944-4951 (2007).
12. Lawrie, C. H. et al. MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int. J. Cancer 121, 1156-1161 (2007).
13. Jongen-Lavrencic, M., Sun, S. M., Dijkstra, M. K., Valk, P. J. & Lowenberg, B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111, 5078-5085 (2008).
14. Navarro, A. et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 111, 2825-2832 (2008).
15. Mao, J., Barrow, J., McMahon, J., Vaughan, J. & McMahon, A. P. An ES cell system for rapid, spatial and temporal analysis of gene function in vitro and in vivo. Nucleic Acids Res. 33, e155 (2005).
16. Zambrowicz, B. P. et al. Disruption of overlapping transcripts in the ROSA bgeo 26 gene trap strain leads to widespread expression of b-galactosidase in mouse embryos and hematopoietic cells. Proc. Natl Acad. Sci. USA 94, 3789-3794 (1997).
17. Petersen, P. H., Zou, K., Hwang, J. K., Jan, Y. N. & Zhong, W. Progenitor cell maintenance requires numb and numblike during mouse neurogenesis. Nature 419, 929-934 (2002).
18. Morse, H. C. et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 100, 246-258 (2002).
19. Pennycook, J. L., Chang, Y., Celler, J., Phillips, R. A. & Wu, G. E. High frequency of normal DJH joints in B cell progenitors in severe combined immunodeficiency mice. J. Exp. Med. 178, 1007-1016 (1993).
20. Li, J. et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin. Cancer Res. 15, 3998-4008 (2009).
21. Seike, M. et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl Acad. Sci. USA 106, 12085-12090 (2009).
22. Imai, Y. et al. Caspase inhibitor, ZVAD-fmk, facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow-bone marrow transplantation. Stem Cells Dev. 10.1089/scd.2009.0251.
23. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199-207 (1999).
24. Yokoyama, K. & Imamoto, F. Transcriptional control of the endogenous MYC protooncogene by antisense RNA. Proc. Natl Acad. Sci. USA 84, 7363-7367 (1987).
25. Li, T., Li, D., Sha, J., Sun, P. & Huang, Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem. Biophys. Res. Commun. 383, 280-285 (2009).
26. Zhu, S. et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 18, 350-359 (2008).
27. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
28. Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nature Genet. 24, 57-60 (2000).
29. Weinstein, I. B. & Joe, A. K. Mechanisms of disease: oncogene addiction\a rationale for molecular targeting in cancer therapy. Nature Clin. Pract. Oncol. 3, 448-457 (2006).